Canada Markets close in 1 hr 42 mins

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
72.25+6.51 (+9.90%)
As of 2:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close65.74
Bid72.04 x 1100
Ask72.14 x 1000
Day's Range66.23 - 74.53
52 Week Range15.52 - 95.21
Avg. Volume10,263,692
Market Cap28.509B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.39
Earnings DateOct. 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est92.54
  • Editor's Pick
    Yahoo Finance Video

    ‘We could see daily averages well over 1,000 deaths per day’ going into winter: doctor

    Brian Garibaldi, JHU Biocontainment Unit Director, joins The Final Round to discuss his thoughts on the rising numbers of cases across the globe and the most recent developments in the vaccine race.

  • Editor's Pick
    Yahoo Finance Video

    Coronavirus Latest: Wednesday, October 28

    As cases rise globally, Sanofi and GlaxoSmithKline have agreed to provide 20 million vaccine doses to the WHO’s COVAX program and the U.S. has agreed to pay $347 million for 300,000 doses of Eli Lilly’s antibody drug. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

  • Why Investors Loved Moderna's Q3 Results
    Motley Fool

    Why Investors Loved Moderna's Q3 Results

    Moderna's (NASDAQ: MRNA) primary focus right now is to hopefully win regulatory approvals or authorizations for coronavirus vaccine mRNA-1273 to make it to the market. Moderna reported revenue in the third quarter of $157.9 million, up a whopping 829% year over year. Perhaps the most important financial measure for Moderna was its cash position at the end of the third quarter.